Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leila Khoja

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Expert Review of Anticancer Therapy|February 26, 2015
Dabrafenib in the treatment of metastatic or unresectable melanomaLeila Khoja, David Hogg
Ecancermedicalscience|September 10, 2016
Adoptive cell therapy and modulation of the tumour microenvironment: new insights from ASCO 2016Leila Khoja, Bishal Gyawali
Cancers|April 20, 2017
AR Signaling and the PI3K Pathway in Prostate CancerMegan Crumbaker, Leila Khoja, Anthony M Joshua
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 24, 2022
Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case seriesAlice Tew, Leila Khoja, Lalit Pallan, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 22, 2023
CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world datasetWilliam Buller, Lalit Pallan, Teresa Chu, et al.
Journal for Immunotherapy of Cancer|August 20, 2015
PembrolizumabLeila Khoja, Marcus O Butler, S Peter Kang, et al.
Journal for Immunotherapy of Cancer|December 18, 2014
Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanomaJoshua S Manusow, Leila Khoja, Nataly Pesin, et al.
Current Oncology (Toronto, Ont.)|August 25, 2015
Increased treatment-related toxicity subsequent to an anti-PD-1 agentLeila Khoja, Marcus Ortho Butler, Mary Anne Chappell, et al.
Plos One|February 3, 2017
Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS)Bethany Pitcher, Leila Khoja, Robert J Hamilton, et al.
Future Oncology (London, England)|January 19, 2017
Malignant bowel obstruction in advanced ovarian cancerEmma Dean, Leila Khoja, Andrew Clamp, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Expert Review of Anticancer Therapy|February 26, 2015
Dabrafenib in the treatment of metastatic or unresectable melanomaLeila Khoja, David Hogg
Ecancermedicalscience|September 10, 2016
Adoptive cell therapy and modulation of the tumour microenvironment: new insights from ASCO 2016Leila Khoja, Bishal Gyawali
Cancers|April 20, 2017
AR Signaling and the PI3K Pathway in Prostate CancerMegan Crumbaker, Leila Khoja, Anthony M Joshua
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 24, 2022
Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case seriesAlice Tew, Leila Khoja, Lalit Pallan, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 22, 2023
CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world datasetWilliam Buller, Lalit Pallan, Teresa Chu, et al.
Journal for Immunotherapy of Cancer|August 20, 2015
PembrolizumabLeila Khoja, Marcus O Butler, S Peter Kang, et al.
Journal for Immunotherapy of Cancer|December 18, 2014
Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanomaJoshua S Manusow, Leila Khoja, Nataly Pesin, et al.
Current Oncology (Toronto, Ont.)|August 25, 2015
Increased treatment-related toxicity subsequent to an anti-PD-1 agentLeila Khoja, Marcus Ortho Butler, Mary Anne Chappell, et al.
Plos One|February 3, 2017
Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS)Bethany Pitcher, Leila Khoja, Robert J Hamilton, et al.
Future Oncology (London, England)|January 19, 2017
Malignant bowel obstruction in advanced ovarian cancerEmma Dean, Leila Khoja, Andrew Clamp, et al.
Pageof 3